{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:19:34Z","timestamp":1777378774775,"version":"3.51.4"},"reference-count":64,"publisher":"SAGE Publications","issue":"1-2","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Anaesth Intensive Care"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Opioid misuse is common, as is opioid agonist treatment of opioid dependence. Almost 3% of Australians and over 3.5% of those living in New Zealand report misuse of analgesics. Over 50,000 Australians receive opioid agonist treatment with methadone or buprenorphine for management of severe opioid use disorder.<\/jats:p>\n                  <jats:p>The perioperative period is an opportunity to identify pre-existing opioid misuse, and to introduce interventions to reduce the risk of development of opioid use disorder. Challenges of acute perioperative pain management or intensive care management of patients receiving opioid agonist treatment include opioid tolerance and ongoing prescribing of methadone or buprenorphine. There has been some ambiguity about the optimal perioperative management of buprenorphine, a partial agonist at the mu receptor.<\/jats:p>\n                  <jats:p>In this article, a framework to identify emerging opioid misuse problems, identify risk of overdose and to manage the opioid-dependent patient on opioid agonist treatment perioperatively or in the intensive care unit is provided. Diagnostic criteria and risk stratification criteria are presented. Management strategies include trauma-informed care, care planning and care coordination with community practitioners and opioid agonist treatment providers. Continuing methadone or buprenorphine perioperatively with additional opioid and non-opioid analgesia is generally recommended. Increased opioid agonist treatment doses may be required on discharge. An algorithm for decisions about opioid agonist treatment management in the intensive care unit based on the risks of opioid withdrawal and toxicity is considered. Strategies for managing the opioid-dependent patient who is not in treatment are also discussed.<\/jats:p>","DOI":"10.1177\/0310057x211066929","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T01:20:11Z","timestamp":1645492811000},"page":"95-107","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Opioid use disorder in anaesthesia and intensive care: Prevention, diagnosis and management"],"prefix":"10.1177","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-3025","authenticated-orcid":false,"given":"Bridin P","family":"Murnion","sequence":"first","affiliation":[{"name":"Drug and Alcohol Services, Western Sydney Local Health District, Sydney, Australia"},{"name":"Faculty of Medicine and Health, University of Sydney, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apo","family":"Demirkol","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia"},{"name":"School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"bibr1-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1507771"},{"key":"bibr2-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1186\/s13741-018-0097-4"},{"key":"bibr3-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.1827"},{"key":"bibr4-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000003477"},{"key":"bibr5-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61036-9"},{"key":"bibr6-0310057X211066929","unstructured":"World Health Organization.\n                      International classification of diseases for mortality and morbidity statistics\n                      (11th revision)\n                      . https:\/\/icd.who.int\/browse11\/l-m\/en (2018, accessed 17 October 2020)."},{"key":"bibr7-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"bibr8-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0137-5"},{"key":"bibr9-0310057X211066929","volume-title":"National Drug Strategy Household Survey 2019. Drug Statistics series no. 32. PHE 270","author":"Australian Institute of Health and Welfare.","year":"2020"},{"key":"bibr10-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1071\/HC12106"},{"key":"bibr11-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12859"},{"key":"bibr12-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.2174\/1573400510666140320000928"},{"key":"bibr13-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.06.027"},{"key":"bibr14-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00868-8"},{"key":"bibr15-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00737"},{"key":"bibr16-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.07.007"},{"key":"bibr17-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-020-00300-7"},{"key":"bibr18-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"bibr19-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1364"},{"key":"bibr20-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002458"},{"key":"bibr21-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1251"},{"key":"bibr22-0310057X211066929","unstructured":"Department of Health.\n                      PBS Expenditure and Prescriptions Report.\n                      https:\/\/www.pbs.gov.au\/statistics\/expenditure-prescriptions\/2018-2019\/PBS_Expenditure_and_Prescriptions_Report_1-July-2018_to_30-June-2019.pdf (2018\u20132019, accessed 22 November 2021)."},{"key":"bibr23-0310057X211066929","volume-title":"Non-medical use of pharmaceuticals: trends, harms and treatment, 2006\u201307 to 2015\u201316. Drug treatment series no.30. Cat. no. HSE 195, 2017","author":"Australian Institute of Health and Welfare","year":"2017"},{"key":"bibr24-0310057X211066929","unstructured":"United Nations.\n                      World Drug Report. Sales No. E\n                      .20.XI.6\n                      . https:\/\/wdr.unodc.org\/wdr2020\/ (2020, accessed 17 October 2020)."},{"key":"bibr25-0310057X211066929","unstructured":"NSW Ministry of Health.\n                      Drug warning: Cocaine and ketamine may contain the dangerous opioids fentanyl and acetylfentanyl\n                      , 2020. https:\/\/www.health.nsw.gov.au\/aod\/public-drug-alerts\/Pages\/cocaine-or-ketamine-contains-fentanyl.aspx (accessed 24 November 2020)."},{"key":"bibr26-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12864"},{"key":"bibr27-0310057X211066929","volume-title":"Australian Drug Trends 2019: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews","author":"Peacock A","year":"2019"},{"key":"bibr28-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.11.026"},{"key":"bibr29-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000548"},{"key":"bibr30-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1807054"},{"key":"bibr31-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx009"},{"key":"bibr32-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"bibr33-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.11.029"},{"key":"bibr34-0310057X211066929","unstructured":"Australian Bureau of Statistics.\n                      Opioid-induced deaths in\n                      Australia\n                      . 2018. https:\/\/www.abs.gov.au\/articles\/opioid-induced-deaths-australia (2019, accessed 22 November 2021)."},{"key":"bibr35-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-2-201001190-00006"},{"key":"bibr36-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1111\/add.13843"},{"key":"bibr37-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1136"},{"key":"bibr38-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"bibr39-0310057X211066929","volume-title":"National Guidelines for Medication-Assisted Treatment of Opioid Dependence","author":"Gowing L","year":"2014"},{"key":"bibr40-0310057X211066929","unstructured":"Lintzeris N, Hayes V, Arunogiri S.\n                      Interim guidance for the delivery of medication assisted treatment of opioid dependence in response to COVID-19: a national response\n                      . https:\/\/www.racp.edu.au\/docs\/default-source\/news-and-events\/covid-19\/interim-guidance-delivery-of-medication-assisted-treatment-of-opiod-dependence-covid-19.pdf?sfvrsn=e36eeb1a_4 (2020, accessed 03 December 2020)."},{"key":"bibr41-0310057X211066929","volume-title":"Pharmaceutical Benefits Scheme","author":"Department of Health","year":"2020"},{"key":"bibr42-0310057X211066929","unstructured":"Pharmac.\n                      New Zealand Pharmaceutical Schedule\n                      . https:\/\/www.pharmac.govt.nz\/medicines\/ (accessed 18 October 2020)."},{"key":"bibr43-0310057X211066929","volume-title":"National Opioid Pharmacotherapy Statistics Annual Data collection 2019. Cat. no. PHE 266","author":"Australian Institute of Health and Welfare.","year":"2020"},{"key":"bibr44-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201909-700IP"},{"key":"bibr45-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED-D-16-00242"},{"key":"bibr46-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-319"},{"key":"bibr47-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1177\/1178221816685087"},{"key":"bibr48-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30430-1"},{"key":"bibr49-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.03870.x"},{"key":"bibr50-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2016.01.032"},{"key":"bibr51-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X1304100212"},{"key":"bibr52-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pny217"},{"key":"bibr53-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2019.06.032"},{"key":"bibr54-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02116.x"},{"key":"bibr55-0310057X211066929","volume-title":"New Zealand Practice Guidelines for Opioid Substitution Treatment","author":"Ministry of Health.","year":"2014"},{"key":"bibr56-0310057X211066929","unstructured":"NSW Health.\n                      NSW Clinical Guidelines: Treatment of Opioid Dependence\n                      . https:\/\/www1.health.nsw.gov.au\/pds\/ActivePDSDocuments\/GL2018_019.pdf (2018, accessed 28 December 2020)."},{"key":"bibr57-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2003.10400007"},{"key":"bibr58-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S109919"},{"key":"bibr59-0310057X211066929","first-page":"229","volume":"4","author":"Mujtaba S","year":"2013","journal-title":"J Cardiovasc Dis Res"},{"key":"bibr60-0310057X211066929","unstructured":"Australian Government Department of Health.\n                      Take Home Naloxone Pilot\n                      . https:\/\/www.health.gov.au\/initiatives-and-programs\/take-home-naloxone-pilot (accessed 22 November 2021)."},{"key":"bibr61-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50818"},{"key":"bibr62-0310057X211066929","unstructured":"Substance and Mental Health Services Administration, US Department of Health and Human Services.\n                      Medication Assisted Treatment. MAT Medications, Counseling and Related Conditions. Naltrexone.\n                      https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/naltrexone (accessed 22 November 2021)."},{"key":"bibr63-0310057X211066929","first-page":"CD001333","volume":"4","author":"Minozzi S","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr64-0310057X211066929","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2008.02.006"}],"container-title":["Anaesthesia and Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0310057X211066929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0310057X211066929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0310057X211066929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:12:15Z","timestamp":1777367535000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0310057X211066929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":64,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1177\/0310057X211066929"],"URL":"https:\/\/doi.org\/10.1177\/0310057x211066929","relation":{},"ISSN":["0310-057X","1448-0271"],"issn-type":[{"value":"0310-057X","type":"print"},{"value":"1448-0271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]}}}